Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science
Author:
Affiliation:
1. Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riß, Germany
2. Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, PO Box 368, Ridgefield, Connecticut 06877-0368, United States
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01884
Reference75 articles.
1. Beyond 2020: Modelling obesity and diabetes prevalence
2. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
3. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
4. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
5. Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis;Metabolism Open;2024-03
2. Phenyl dialkynylcarbinols, a Bioinspired Series of Synthetic Antitumor Acetylenic Lipids;Journal of Medicinal Chemistry;2023-10-10
3. Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13;Nature Communications;2023-08-24
4. 17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease;Pharmacology & Therapeutics;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3